{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:51:13Z","timestamp":1770526273145,"version":"3.49.0"},"reference-count":49,"publisher":"Japan Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej13-0083","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T06:04:56Z","timestamp":1372917896000},"page":"1131-1144","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study"],"prefix":"10.1507","volume":"60","author":[{"given":"Akira","family":"Shimatsu","sequence":"first","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tai","sequence":"additional","affiliation":[{"name":"Tai Clinic, Osaka 555-0001, Japan"},{"name":"Medical Science, Eli Lilly Japan K.K., Kobe 651-0086, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Imori","sequence":"additional","affiliation":[{"name":"Global Patient Safety Japan, Eli Lilly Japan K.K., Kobe 651-0086, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuichiro","family":"Ihara","sequence":"additional","affiliation":[{"name":"Medical Science, Eli Lilly Japan K.K., Kobe 651-0086, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Taketsuna","sequence":"additional","affiliation":[{"name":"Statistical Science, Eli Lilly Japan K.K., Kobe 651-0086, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Funai","sequence":"additional","affiliation":[{"name":"Science Communications, Eli Lilly Japan K.K., Kobe 651-0086, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Tanaka Growth Clinic, Tokyo 154-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nippon Medical School, Tokyo 113-8603, Japan"},{"name":"Tokyo Rosai Hospital, Tokyo 143-0013, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Irie","sequence":"additional","affiliation":[{"name":"Emeritus Professor, Toho University, Tokyo 112-0001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Chihara","sequence":"additional","affiliation":[{"name":"Hyogo Prefectural Kakogawa Medical Center, Hyogo 675-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Carroll PV, Christ ER, Bengtsson B&Aring;, Carlsson L, Christiansen JS, <i>et al.<\/i> (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. <i>J Clin Endocrinol Metab<\/i> 83: 382-395.","DOI":"10.1210\/jcem.83.2.4594"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Doga M, Bonadonna S, Gola M, Mazziotti G, Giustina A (2006) Growth hormone deficiency in the adult. <i>Pituitary<\/i> 9: 305-311.","DOI":"10.1007\/s11102-006-0410-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Monson JP (2003) Long-term experience with GH replacement therapy: Efficacy and safety. <i>Eur J Endocrinol<\/i> 148 Suppl 2: S9-14.","DOI":"10.1530\/eje.0.148s009"},{"key":"4","unstructured":"4. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, <i>et al<\/i>. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. <i>J Clin Endocrinol Metab<\/i> 82: 82-88."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, <i>et al<\/i>. (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). <i>J Clin Endocrinol Metab<\/i> 89: 1684-1693.","DOI":"10.1210\/jc.2003-030134"},{"key":"6","unstructured":"6. Bj&ouml;rk S, J&ouml;nsson B, Westphal O, Levin JE (1989) Quality of life of adults with growth hormone deficiency: a controlled study. <i>Acta Paediatr Scand Suppl<\/i> 356: 55-59; discussion 60, 73-4."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson B&Aring; (1994) Decreased psychological well-being in adult patients with growth hormone deficiency. <i>Clin Endocrinol (Oxf)<\/i> 40: 111-116.","DOI":"10.1111\/j.1365-2265.1994.tb02452.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wallymahmed ME, Baker GA, Humphris G, Dewey M, MacFarlane IA (1996) The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. <i>Clin Endocrinol (Oxf)<\/i> 44: 403-411.","DOI":"10.1046\/j.1365-2265.1996.704523.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shimatsu A, Tai S, Tanaka T, Fujieda K, Teramoto A, <i>et al.<\/i> (2011) Clinical characteristics of Japanese adults with growth hormone deficiency: a HypoCCS database study. <i>Endocr J<\/i> 58: 325-333.","DOI":"10.1507\/endocrj.K10E-363"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nilsson AG, Svensson J, Johannsson G (2007) Management of growth hormone deficiency in adults. <i>Growth Horm IGF Res<\/i> 17: 441-462.","DOI":"10.1016\/j.ghir.2007.05.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, <i>et al.<\/i> (2003) Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. <i>J Clin Endocrinol Metab<\/i> 88: 4158-4167.","DOI":"10.1210\/jc.2002-021792"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Peker Y, Svensson J, Hedner J, Grote L, Johannsson G (2006) Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6 months of GH replacement therapy. <i>Clin Endocrinol (Oxf)<\/i> 65: 98-105.","DOI":"10.1111\/j.1365-2265.2006.02555.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Koltowska-H&auml;ggstr&ouml;m M, Mattsson AF, Shalet SM (2009) Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. <i>Eur J Endocrinol<\/i> 161 Suppl 1: S51-64.","DOI":"10.1530\/EJE-09-0266"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, <i>et al.<\/i> (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 96: 1587-1609.","DOI":"10.1210\/jc.2011-0179"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chihara K, Fujieda K, Shimatsu A, Miki T, Tachibana K (2010) Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: A randomized, placebo-controlled trial. <i>Growth Horm IGF Res<\/i> 20: 205-211.","DOI":"10.1016\/j.ghir.2010.01.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, <i>et al.<\/i> (2006) Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: A randomised, placebo-controlled study. <i>Growth Horm IGF Res<\/i> 16: 132-142.","DOI":"10.1016\/j.ghir.2006.03.012"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chihara K, Kato Y, Shimatsu A, Tanaka T, Kohno H (2008) Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency. <i>Growth Horm IGF Res<\/i> 18: 394-403.","DOI":"10.1016\/j.ghir.2008.02.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, <i>et al.<\/i> (2004) Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial. <i>Eur J Endocrinol<\/i> 151: 343-350.","DOI":"10.1530\/eje.0.1510343"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, <i>et al.<\/i> (2005) An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. <i>Eur J Endocrinol<\/i> 153: 57-65.","DOI":"10.1530\/eje.1.01936"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Urushihara H, Fukuhara S, Tai S, Morita S, Chihara K (2007) Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement. <i>Eur J Endocrinol<\/i> 156: 637-645.","DOI":"10.1530\/EJE-07-0016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, <i>et al.<\/i> (2008) Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD). <i>Growth Horm IGF Res<\/i> 18: 307-317.","DOI":"10.1016\/j.ghir.2007.12.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, <i>et al.<\/i> (2009) Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. <i>J Clin Endocrinol Metab<\/i> 94: 392-399","DOI":"10.1210\/jc.2008-0713"},{"key":"23","unstructured":"23. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, <i>et al.<\/i> (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database. <i>J Clin Endocrinol Metab<\/i> 87: 1600-1606."},{"key":"24","unstructured":"24. Humatrope [prescribing information] (2010) Kobe, Japan: Eli Lilly Japan K.K."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, <i>et al.<\/i> (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. <i>J Diabet Invest<\/i> 3: 39-40.","DOI":"10.1111\/j.2040-1124.2012.00207.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. <i>J Clin Epidemiol<\/i> 51: 1037-1044.","DOI":"10.1016\/S0895-4356(98)00095-X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Suzukamo Y, Noguchi H, Takahashi N, Shimatsu A, Chihara K,<i> et al.<\/i> (2006) Validation of the Japanese version of the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). <i>Growth Horm IGF Res<\/i> 16: 340-347.","DOI":"10.1016\/j.ghir.2006.09.002"},{"key":"28","unstructured":"28. Shimatsu A, Chihara K, Hizuka N, Teramoto A, Tanaka T, <i>et al.<\/i> (2007) Reference intervals of serum insulin-like growth factor-I in adult Japanese population: calculated with LMS methods. <i>Horumon to Rinsho <\/i>55: 393-399 (in Japanese)."},{"key":"29","unstructured":"29. Fukuhara S, Suzukamo Y, Manual of SF-36v2 Japanese version. 2009, Kyoto: Institute for Health Outcomes and Process Evaluation Research."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kaji H, Sakurai T, Iguchi G, Murata M, Kishimoto M, <i>et al.<\/i> (2002) Adult growth hormone deficiency in Japan: Results of investigation by questionnaire. <i>Endocr J<\/i> 49: 597-604.","DOI":"10.1507\/endocrj.49.597"},{"key":"31","unstructured":"31. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, <i>et al.<\/i> (1996) The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. <i>J Clin Endocrinol Metab<\/i> 81: 1575-1581."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ezzat S, Fear S, Gaillard RC, Gayle C, Marcovitz S, <i>et al.<\/i> (2003) Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults. <i>Eur J Endocrinol<\/i> 149: 499-509.","DOI":"10.1530\/eje.0.1490499"},{"key":"33","unstructured":"33. Barbosa EJ, Koranyi J, Filipsson H, Bengtsson B&Aring;, Boguszewski CL, <i>et al.<\/i> (2010) Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. <i>Eur J Endocrinol <\/i>162: 869-878."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mukherjee A, Adams JE, Smethurst L &amp; Shalet SM. (2005) Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults. <i>Eur J Endocrinol <\/i>153: 661-668.","DOI":"10.1530\/eje.1.02017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Abs R, Bengtsson B&Aring;, Hernberg-Stahl E, Monson JP, Tauber JP, <i>et al.<\/i> (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety. <i>Clin Endocrinol (Oxf)<\/i> 50: 703-713.","DOI":"10.1046\/j.1365-2265.1999.00695.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, <i>et al.<\/i> (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. <i>J Clin Endocrinol Metab<\/i> 98: 980-988.","DOI":"10.1210\/jc.2012-2684"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, <i>et al.<\/i> (2002) Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? <i>Eur J Endocrinol<\/i> 146: 807-811.","DOI":"10.1530\/eje.0.1460807"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Buchfelder M, Kann PH, W&uuml;ster C, Tuschy U, Saller B, <i>et al.<\/i> (2007) Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: A case control study. <i>Eur J Endocrinol<\/i> 157: 149-156.","DOI":"10.1530\/EJE-07-0164"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, <i>et al.<\/i> (2010) Long-term safety of recombinant human growth hormone in children. <i>J Clin Endocrinol Metab<\/i> 95: 167-177.","DOI":"10.1210\/jc.2009-0178"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, <i>et al.<\/i> (1992) Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. <i>BMJ<\/i> 304: 1343-1346.","DOI":"10.1136\/bmj.304.6838.1343"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, <i>et al.<\/i> (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: An analysis from the Hypopituitary Control and Complications Study. <i>Eur J Endocrinol<\/i> 165: 217-223.","DOI":"10.1530\/EJE-11-0286"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, <i>et al.<\/i> (2005) Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: A population-based prospective study in the JPHC study cohort I. <i>Diabetic Med<\/i> 22: 323-331.","DOI":"10.1111\/j.1464-5491.2004.01403.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Noda M, Kato M, Takahashi Y, Matsushita Y, Mizoue T, <i>et al.<\/i> (2010) Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study - suggestion for the threshold for impaired fasting glucose among Japanese. <i>Endocr J<\/i> 57: 629-637.","DOI":"10.1507\/endocrj.K10E-010"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, <i>et al.<\/i> (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: A surveillance database analysis. <i>J Clin Endocrinol Metab<\/i> 96: 2255-2261.","DOI":"10.1210\/jc.2011-0448"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Luger A, Mattsson AF, Koltowska-H&auml;ggstr&ouml;m M, Thunander M, G&oacute;th M, <i>et al.<\/i> (2012) Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: A long-term observational study. <i>Diabetes Care<\/i> 35: 57-62.","DOI":"10.2337\/dc11-0449"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, <i>et al.<\/i> (2010) Lifetime risk of stroke in Japan. <i>Stroke<\/i> 41: 1552-1554.","DOI":"10.1161\/STROKEAHA.110.581363"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, <i>et al.<\/i> (2010) Lifetime risk of acute myocardial infarction in Japan. <i>Circ Cardiovasc Qual Outcomes<\/i> 3: 701-703.","DOI":"10.1161\/CIRCOUTCOMES.109.930776"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Svensson J, Bengtsson B&Aring;, Rosen T, Oden A, Johannsson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. <i>J Clin Endocrinol Metab<\/i> 89: 3306-3312.","DOI":"10.1210\/jc.2003-031601"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Erfurth EM, Hagmar L (2005) Cerebrovascular disease in patients with pituitary tumors. <i>Trends Endocrinol Metab<\/i> 16: 334-342.","DOI":"10.1016\/j.tem.2005.07.004"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/10\/60_EJ13-0083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:39:02Z","timestamp":1618295942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/10\/60_EJ13-0083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0083","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}